Skip to content

CLDN18.2 Targeting PET Imaging in Patients With Gastrointestinal Tumors

CLDN18.2 Targeting 124I-18B10(10L) PET Imaging in Patients With Gastrointestinal Tumors

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04883970
Enrollment
15
Registered
2021-05-12
Start date
2021-05-13
Completion date
2024-05-31
Last updated
2024-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Cancer

Brief summary

The objective of the study is to constrcut a noninvasive approach 124I-18B10(10L) PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from CLDN18.2 targeting treatment.

Interventions

OTHER124I-18B10(10L) PET/CT

Study participants will undergo 124I-18B10(10L) PET/CT scans

Sponsors

Peking University Cancer Hospital & Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\. Aged \>18 years old; ECOG 0 or 1; * 2\. Patients with Gastrointestinal tumors; * 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1); * 4\. life expectancy \>=12 weeks.

Exclusion criteria

* 1\. Significant hepatic or renal dysfunction; * 2\. Is pregnant or ready to pregnant; * 3\. Cannot keep their states for half an hour; * 4\. Refusal to join the clinical study; * 5\. Suffering from claustrophobia or other mental diseases; * 6\. Any other situation that researchers think it is not suitable to participate in the experiment.

Design outcomes

Primary

MeasureTime frame
Standardized uptake value(SUV)2 years

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026